Close
  • Latest News
  • Cybersecurity
  • Big Data and Analytics
  • Cloud
  • Mobile
  • Networking
  • Storage
  • Applications
  • IT Management
  • Small Business
  • Development
  • Database
  • Servers
  • Android
  • Apple
  • Innovation
  • Blogs
  • PC Hardware
  • Reviews
  • Search Engines
  • Virtualization
Read Down
Sign in
Close
Welcome!Log into your account
Forgot your password?
Read Down
Password recovery
Recover your password
Close
Search
Menu
Search
  • Latest News
  • Cybersecurity
  • Big Data and Analytics
  • Cloud
  • Mobile
  • Networking
  • Storage
  • Applications
  • IT Management
  • Small Business
  • Development
  • Database
  • Servers
  • Android
  • Apple
  • Innovation
  • Blogs
  • PC Hardware
  • Reviews
  • Search Engines
  • Virtualization
More
    Home Applications
    • Applications
    • Development
    • Networking

    IBM Supercomputers Help Researchers Find Cure for the Common Cold

    By
    Darryl K. Taft
    -
    July 16, 2012
    Share
    Facebook
    Twitter
    Linkedin

      IBM technology is helping fight the common cold.

      Researchers in Melbourne, Australia, are now simulating in 3D the motion of the complete human rhinovirus (HRV), the most frequent cause of the common cold, using Australia€™s fastest supercomputer, an IBM Blue Gene/Q.

      A new antiviral drug to treat rhinovirus infections is being developed by Melbourne company Biota Holdings Ltd., targeted for those with these existing conditions where the common cold is a serious threat to their health and could prove fatal. In conjunction with researchers at the IBM Research Collaboratory for Life Sciences€“Melbourne, scientists from St. Vincent€™s Institute of Medical Research and the University of Melbourne are using information on how the new drug works to create a 3D simulation of the complete rhinovirus on IBM supercomputing technology.

      To help pave the way for new drug development, researchers are working to build a fully atomistic, three-dimensional simulation of HRV. According to IBM, these calculations are the first to include not only the 3 million-plus atoms of the rhinovirus capsid€”or outer shell€”and their aqueous environment, but also the virus€™ RNA genome, that packet of genetic information necessary for the virus to replicate.

      A new antiviral drug to treat rhinovirus infections is being developed by Melbourne company Biota Holdings Ltd., targeted for those with conditions where the common cold is a serious threat to their health and could prove fatal.

      Rhinovirus infection is linked to about 70 percent of all asthma exacerbations, with more than 50 percent of these patients requiring hospitalization. Furthermore, over 35 percent of patients with acute chronic obstructive pulmonary disease (COPD) are hospitalized each year due to respiratory viruses including rhinovirus.

      A team of researchers led by Professor Michael Parker from St. Vincent€™s Institute of Medical Research (SVI) and the University of Melbourne are now using information on how the new drug works to create a 3D simulation of the complete rhinovirus using Australia€™s fastest supercomputer.

      €œOur recently published work with Biota shows that the drug binds to the shell that surrounds the virus, called the capsid,€ Parker said in a statement. €œBut that work doesn€™t explain in precise detail how the drug and other similar acting compounds work.€

      Professor Parker and his team are working on the newly installed IBM Blue Gene/Q at the University of Melbourne with computational biologists from IBM and the Victorian Life Sciences Computation Initiative (VLSCI).

      In production since July 1, 2012, the IBM Blue Gene/Q is the most powerful supercomputer dedicated to life sciences research in the Southern Hemisphere and currently ranked the fastest in Australia.

      €œThe IBM Blue Gene/Q will provide us with extraordinary 3D computer simulations of the whole virus in a time frame not even dreamt of before,€ Parker said. €œSupercomputer technology enables us to delve deeper in the mechanisms at play inside a human cell, particularly how drugs work at a molecular level. €œThis work offers exciting opportunities for speeding up the discovery and development of new antiviral treatments and hopefully will save many lives around the world,€ he said.

      Professor Parker said that previous efforts have only been able to focus on running smaller simulations on just parts of the virus. However, Professor James McCluskey, deputy vice chancellor for research at the University of Melbourne, said: €œThe work on rhinovirus is an example of how new approaches to treat disease will become possible with the capacity of the IBM Blue Gene Q, exactly how we hoped this extraordinary asset would be utilized by the Victorian research community in collaboration with IBM. €œThis is a terrific facility for Victorian life science researchers, further strengthening Victoria€™s reputation as a leading biotechnology centre,€ he said.

      John Wagner, Ph.D., manager of the IBM Research Collaboratory for Life Sciences-Melbourne, co-located at the VLSCI, said these types of simulations are the way of the future for drug discovery. €œThis is the way we do biology in the 21st Century,€ he said.

      The newly operational IBM Blue Gene/Q hosted by the University of Melbourne at the VLSCI is ranked 31st on the prestigious global TOP500 list. The TOP500 table nominates the 500 most powerful computer systems in the world.

      The VLSCI is an initiative of the Victorian Government in partnership with the University of Melbourne and the IBM Life Sciences Research Collaboratory, Melbourne.

      Avatar
      Darryl K. Taft
      Darryl K. Taft covers the development tools and developer-related issues beat from his office in Baltimore. He has more than 10 years of experience in the business and is always looking for the next scoop. Taft is a member of the Association for Computing Machinery (ACM) and was named 'one of the most active middleware reporters in the world' by The Middleware Co. He also has his own card in the 'Who's Who in Enterprise Java' deck.

      MOST POPULAR ARTICLES

      Android

      Samsung Galaxy XCover Pro: Durability for Tough...

      Chris Preimesberger - December 5, 2020 0
      Have you ever dropped your phone, winced and felt the pain as it hit the sidewalk? Either the screen splintered like a windshield being...
      Read more
      Cloud

      Why Data Security Will Face Even Harsher...

      Chris Preimesberger - December 1, 2020 0
      Who would know more about details of the hacking process than an actual former career hacker? And who wants to understand all they can...
      Read more
      Cybersecurity

      How Veritas Is Shining a Light Into...

      eWEEK EDITORS - September 25, 2020 0
      Protecting data has always been one of the most important tasks in all of IT, yet as more companies become data companies at the...
      Read more
      Big Data and Analytics

      How NVIDIA A100 Station Brings Data Center...

      Zeus Kerravala - November 18, 2020 0
      There’s little debate that graphics processor unit manufacturer NVIDIA is the de facto standard when it comes to providing silicon to power machine learning...
      Read more
      Apple

      Why iPhone 12 Pro Makes Sense for...

      Wayne Rash - November 26, 2020 0
      If you’ve been watching the Apple commercials for the past three weeks, you already know what the company thinks will happen if you buy...
      Read more
      eWeek


      Contact Us | About | Sitemap

      Facebook
      Linkedin
      RSS
      Twitter
      Youtube

      Property of TechnologyAdvice.
      Terms of Service | Privacy Notice | Advertise | California - Do Not Sell My Information

      © 2021 TechnologyAdvice. All Rights Reserved

      Advertiser Disclosure: Some of the products that appear on this site are from companies from which TechnologyAdvice receives compensation. This compensation may impact how and where products appear on this site including, for example, the order in which they appear. TechnologyAdvice does not include all companies or all types of products available in the marketplace.

      ×